Adagene Licenses its mAb Masking Technology to Exelixis in Collaboration

Suzhou 's Adagene will license its SAFEbody™ technology platform, which generates masked versions of monoclonal antibodies, to Exelixis for use in Exelixis’ ADC preclinical pipeline. Exelixis will make an upfront payment of $11 million to Adagene and will have the ability to nominate two targets during the collaboration. Adagene will be eligible for development and commercialization milestones, as well as royalties on net sales of any developed products. Exelixis is headquartered in Alameda , CA . More details.... Stock Symbol: (NSDQ: EXEL) Share this with colleagues: // //